<DOC>
	<DOCNO>NCT01505673</DOCNO>
	<brief_summary>The purpose study evaluate whether addition liraglutide 1.8 mg/day high-dose insulin regimen ( &gt; 1.8 units/kg/day ) patient uncontrolled ( HbA1c &gt; 7.5 % ) type 2 diabetes mellitus improve blood sugar control . It also evaluate effect liraglutide liver pancreatic fat content , explore mechanism blood sugar improvement assess weight pancreatic hormone release , assess blood pressure , lipid profile , liver function . Finally look patient quality life safety .</brief_summary>
	<brief_title>Adding Liraglutide High Dose Insulin : Breaking Cycle</brief_title>
	<detailed_description>Type 2 diabetes progressive disease incessant beta-cell dysfunction often ultimately require insulin treatment . Patients require high insulin dosage represent particular treatment challenge often uncontrolled glycemia despite progressive dose increase especially prone insulin relate lipotoxicity weight gain . Glucagon-like peptide agonist ( GLP-1 ) liraglutide many action position break vicious cycle population follow mechanism : ( 1 ) weight loss ; ( 2 ) improve hepatic steatosis ; ( 3 ) improve pancreatic steatosis ; ( 4 ) decrease glucagon level ; ( 5 ) improve beta-cell function . The purpose study demonstrate liraglutide effective safe add high dose insulin treatment regimen . Liraglutide improve glycemic control , weight , metabolic parameter , well patient satisfaction , minimal adverse event . The study also propose study mechanism improvement might occur , especially beta-cell function , glucagon level , hepatic pancreatic fat content .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Insulin dose &gt; 1.8 units/kg/day ( represent total daily insulin dose , regardless formulation , regimen , number daily shot ) HbA1c ≥ 7.5 % ≤ 11 % Age ≥ 18 Stable comorbidities stable treatment regimens Stable dose oral hypoglycemics ≥ 3 month prior enrollment Ability provide inform consent trialrelated activity Type 1 diabetes mellitus Any contraindication MRI procedure ( metallic implant , severe claustrophobia , pregnancy , unable lie still hard table duration procedure , weight 400 lb limit MRI table , magnet 's inner circumference small large body circumference ) History pancreatic disease might interfere pancreatic TG measurement ( i.e . pancreatitis , tumor , cyst , type 1 diabetes , pancreatic surgery ) End Stage Renal Disease dialysis due increase risk hypoglycemia , possible interference accurate measurement HbA1c Incretin therapy ( GLP1 agonist DPPIV inhibitor ) Unstable decompensated comorbidities Personal family history medullary thyroid carcinoma MEN2 syndrome Severe gastroparesis Pregnancy , breast feeding , intention become pregnant , use adequate contraceptive measure Organ transplant recipient wait list candidate Steroid use ( current potential use trial ) Known/suspected allergy trial medication , excipients , relate product Contraindications study medication , word specifically state product 's prescribing information NonEnglish speaking volunteer since interpreter available safety volunteer could jeopardize adequate reliable communication possible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Insulin</keyword>
	<keyword>Glucagon-like peptide</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Beta-Cell</keyword>
	<keyword>pancreatic steatosis</keyword>
	<keyword>hepatic steatosis</keyword>
</DOC>